Natural killer cell activation by respiratory syncytial virus‐specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc‐glycosylation
Open Access
- 1 January 2020
- journal article
- research article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 9 (2) , e1112
Abstract
Objectives: Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants, and there is no vaccine available. In early life, the most important contributors to protection against infectious diseases are the innate immune response and maternal antibodies. However, antibody‐mediated protection against RSV disease is incompletely understood, as both antibody levels and neutralisation capacity correlate poorly with protection. Since antibodies also mediate natural killer (NK) cell activation, we investigated whether this functionality correlates with RSV disease.Methods: We performed an observational case–control study including infants hospitalised for RSV infection, hernia surgery or RSV‐negative respiratory viral infections. We determined RSV antigen‐specific antibody levels in plasma using a multiplex immunoassay. Subsequently, we measured the capacity of these antibodies to activate NK cells. Finally, we assessed Fc‐glycosylation of the RSV‐specific antibodies by mass spectrometry.Results: We found that RSV‐specific maternal antibodies activate NK cells in vitro. While concentrations of RSV‐specific antibodies did not differ between cases and controls, antibodies from infants hospitalised for severe respiratory infections (RSV and/or other) induced significantly less NK cell interferon‐γ production than those from uninfected controls. Furthermore, NK cell activation correlated with Fc‐fucosylation of RSV‐specific antibodies, but their glycosylation status did not significantly differ between cases and controls.Conclusion: Our results suggest that Fc‐dependent antibody function and quality, exemplified by NK cell activation and glycosylation, contribute to protection against severe RSV disease and warrant further studies to evaluate the potential of using these properties to evaluate and improve the efficacy of novel vaccines.Keywords
All Related Versions
Funding Information
- Landsteiner Foundation for Blood Transfusion Research (LSBR 1721)
- ZonMw (451001021)
- Stichting Sanquin Bloedvoorziening (PPOC‐15‐12)
- Rijksinstituut voor Volksgezondheid en Milieu (SPR S/112008)
This publication has 71 references indexed in Scilit:
- Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory DiseaseScience Translational Medicine, 2013
- Affinity-Purified Respiratory Syncytial Virus Antibodies from Intravenous Immunoglobulin Exert Potent Antibody-Dependent Cellular CytotoxicityPLOS ONE, 2013
- Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activityJournal of Clinical Investigation, 2013
- Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene FamilyJournal of Virology, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Natural Killer Cells Are Involved in Acute Lung Immune Injury Caused by Respiratory Syncytial Virus InfectionJournal of Virology, 2012
- Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer CellsJournal of Virology, 2010
- Skyline: an open source document editor for creating and analyzing targeted proteomics experimentsBioinformatics, 2010
- Natural killer cells in infection and inflammation of the lungImmunology, 2009
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009